RxDoctor Payments DataLook up a doctor →

Thomas Leist, MD

Neurology · Philadelphia, PANPI 1801816681

Payments from drug & device makers

$5,763,497in general payments, 2019–2025

Across 1,828 payments — averaging $3152.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3M
  • Bristol Myers Squibb$471K
  • Biogen$429K
  • Roche Products Limited$249K
  • Sanofi$243K
  • EMD Serono, Inc.$218K
  • plus $1.1M from 30 others
$12,867in research payments, 2019–2025

Across 16 payments — averaging $804.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$7K
  • F. Hoffmann-la Roche AG$4K
  • AbbVie$734
  • EMD Serono, Inc.$495
  • Sanofi US Services Inc.$285

What the payments were for

  • Consulting fees$381,94726%
  • Speaking & faculty fees$880,48261%
  • Travel & lodging$111,0258%
  • Food & beverage$30,4482%
  • Education$35,8532%
  • Gifts$2,7330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,763,497 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$88,641
Medicare patients
284
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab97$900,631
AubagioTeriflunomide53$492,006
Teriflunomide122$321,499
CopaxoneGlatiramer Acetate38$267,282
EnspryngSatralizumab-Mwge12$223,995
Glatiramer Acetate63$178,797
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5020$156,532
GlatopaGlatiramer Acetate31$103,216
Avonex (4 Pack)Interferon Beta-1a13$103,133
Dalfampridine ErDalfampridine144$97,440
Dimethyl Fumarate38$61,700
Nurtec OdtRimegepant Sulfate11$21,950
FingolimodFingolimod Hcl16$11,484
Baclofen244$8,342
AuvelityDextromethorphan Hbr/Bupropion11$6,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$243,449$492,00653 claims
Teva Pharmaceuticals USA, Inc.Copaxone$18,934$267,28238 claims
Genentech USA, Inc.Enspryng$165,819$223,99512 claims
BiogenAvonex (4 Pack)$429,284$103,13313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →